Malaria Infections and Infestations Malaria
Conditions
Interventions
Villages (clusters) will be allocated to one of two treatments through restricted randomization based on village size and malaria prevalence in children between the ages of 6 months in 10 years. There
Sponsors
The Pennsylvania State University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 6 months – 10 years old 2. Resident in houses enrolled in the study 3. Whose parents/guardians give written, informed consent for their child to be included in the study 4. In the case of school-aged children, only those who live in their villages throughout the school term will be eligible for enrollment 5. For the results to be as generalizable as possible, no distinctions will be made in terms of medical condition, physical health, gender or ethnic group
Exclusion criteria
Exclusion criteria: 1. For whom informed consent is not or cannot be provided by a parent or guardian 2. Who are under 6 months or over 10 years at any point in the study 3. Expected to be non-resident during a significant part of the transmission season
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Malaria incidence will be monitored in cohorts of children (6 months through 10 years old) through active case detection (ACD) with monthly visits during the dry season (November – April) and fortnightly visits during the rainy reason (May – October). Clinical malaria will be defined as a positive malaria rapid diagnostic test (RDT) and an axillary body temperature of =37.5oC. Malaria infections will be confirmed by PCR of blood samples for malaria parasite DNA. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Clinical malaria incidence in all children will be measured by clinic visits throughout the course of two year monitoring period. Malaria diagnosis will be defined as any child presenting with an axillary body temperature of =37.5oC and a positive Rapid Diagnostic Test (RDT). 2. Prevalence of anemia and respiratory infections in the study cohort, measured twice yearly (April and November) for two years. Anemia will be testing using blood samples and the Hemocue Hb system and defined as moderate (7 – 9.9 g/dL hemoglobin) to severe (<7 g/dL hemoglobin) anemia. Respiratory infections will be diagnosed based on clinical symptoms including coughing, and either a raised age-specific respiratory rate or chest indrawing. 3. Malaria vector densities will be measured by CDC light traps for two nights every month, and by human landing catches for 2 nights every two months. Mosquito species identification will be done based on morphology and confirmed by PCR. Parity rates will be measured through a visual inspection of ovaries and sporozoite prevalence will be measured by ELISA in a subset of the mosquito catches. Prevalence of kdr and ace1 resistance alleles will also be measured through PCR in a subset of the catches. 4. Data loggers will be used to record hourly temperature and relative humidity in a subset of study houses in each village to determine whether house modifications affect indoor microclimate. A commercial air sampler will be used to assess whether house modifications affect indoor air quality every month from baseline to two years 5. Public attitudes about malaria, its prevention, and whether eave tube technology is acceptable to the residents will be measured through surveys from baseline to two years | — |
Countries
Cote d'Ivoire
Outcome results
None listed